Skip Navigation LinksHome > Studies > A4 Study  
 

                                                  

You can read additional information about the A4 Study on the A4 Study website!

HTTP://A4Study.org

What is the A4 Study?
The A4 Study is a clinical study for older individuals (ages 65-85) who have normal thinking and memory function but who may be at risk for developing Alzheimer's disease (AD) memory loss sometime in the future. The A4 study is for people without any outward signs of Alzheimer's disease, and is designed to evaluate the effectiveness, safety and tolerability of an investigational drug for AD. The purpose of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the”A4 study” for short) is to test whether a new investigational treatment can slow the memory loss caused by Alzheimer’s disease. The overall goal of the A4 study is to test whether decreasing amyloid with antibody investigational treatment can help slow the memory loss associated with amyloid buildup in some people.

The A4 Study lasts for three years, and participants will be assigned at random to receive either the investigational drug or a placebo and will be monitored over that period.

In general, you may be eligible to join the A4 Study if you:

  • Are 65 to 85 years old
  • Have normal thinking and memory abilities
  • Have a study partner (someone who has weekly contact with you and is willing to answer questions once a year).

The A4 Study will begin to enroll participants at more than 60 sites throughout the U.S. and Canada and in Australia beginning in the Spring of 2014. Please visit A4Study.org for additional information. We expect sites across North America to be ready to screen and enroll study participants during the first half 2014.

Who is sponsoring the study?
The A4 study is a landmark public-private partnership, funded by the National Institute on Aging/NIH, Eli Lilly and Company, and several philanthropic organizations. The A4 study is coordinated by the Alzheimer's Disease Cooperative Study, located at the University of California, San Diego.

United States of America

Alabama North Carolina
University of Alabama, Birmingham Wake Forest University
Arizona New Hampshire
Banner Alzheimer's Institute Dartmouth Medical Center
Banner Sun Health Research Institute Nevada
California Cleveland Clinic Lou Ruvo Center for Brain Health
Stanford University School of Medicine New York
UC Irvine – Institute for Memory Impairments & Neurological Disorders Columbia University
University of California, Davis Dent Neurologic Institute
University of California, Irvine Mount Sinai School of Medicine
University of California, Irvine – Brain Imaging Center Nathan Kline Institute for Psychiatric Research
University of California, San Diego New York University Medical Center
University of California, San Francisco University of Rochester Medical Center
University of California, Los Angeles Weill Cornell Memory Disorders Program
University of Southern California
Connecticut North Carolina
Yale University Wake Forest University
District of Columbia Ohio
Georgetown University Case Western Reserve University
Howard University
Florida Oregon
Mayo Clinic, Jacksonville Oregon Health Sciences University
Premiere Research Institute Oklahoma
University of South Florida - Health Byrd Alzheimer Institute Tulsa Clinical research
Wien Center for Clinical Research
Georgia Pennsylvania
Emory University University of Pennsylvania
Iowa University of Pittsburgh
University of Iowa Drexel University College of Medicine
Illinois Rhode Island
Northwestern University Rhode Island Hospital
Rush University Medical Center Butler Hospital Memmory and Aging Program
Indiana South Carolina
Indiana University Roper St. Francis Hospital
Kansas Texas
University of Kansas Baylor College of Medicine
Kentucky University of Texas, Southwestern
University of Kentucky Utah
Massachusetts University of Utah
Boston University Washington
Brigham and Women's Hospital University of Washington
Maryland Michigan
Johns Hopkins University Wisconsin
University of Wisconsin
University of Michigan, Ann Arbor
Minnesota
Mayo Clinic, Rochester
Missouri
Washington University, St. Louis
Nebraska
University of Nebraska
Canada
British Columbia
University of British Columbia, Clinic for AD & Related

Ontario
Parkwood Hospital
Sunnybrook Health Science Centre
Toronto Memory Program

Australia
Victoria
University of Melbourne

Meet the A4 Principal Investigator

Reisa Sperling, M.D. is a Professor in Neurology at Harvard Medical School and the Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital. She is a board certified neurologist who has been working in cognitive aging and Alzheimer's disease research for over 15 years. Her imaging work is focused on elucidating the neural underpinnings of memory loss and detecting the earliest brain changes associated with early Alzheimer's disease. She is the Principal Investigator on a National Institute on Aging (NIA) funded Program Project: the Harvard Aging Brain Study and serves as the Director of the Alzheimer’s Disease Neuroimaging Program at Massachusetts General Hospital. Dr. Sperling had the honor of serving as the Chair of the NIA-Alzheimer’s Association working group to develop the research criteria for “Preclinical Alzheimer’s disease” published in 2011.

Dr. Sperling leads the is the Project Director of the A4 Study . You can learn more about Dr. Sperling’s work by following the link below to the Massachusetts ADRC.

Who is sponsoring the A4 Study?

The A4 study is a landmark public-private partnership, funded by the National Institute on Aging, Eli Lilly and Company, and several philanthropic organizations. The A4 trial is coordinated by the Alzheimer's Disease Cooperative Study, located at the University of California, San Diego.

Contact the A4 Study
Email: Brainlink@ucsd.edu